Bremelanotide
Bremelanotide (Vyleesi)
A melanocortin receptor agonist FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Administered as needed before sexual activity.
Typical Cost
$900-1200/month
Status
Research
Peptide Profile
Bremelanotide
Mechanism of Action
Activates melanocortin receptors in the CNS to increase sexual desire and arousal. Works through neural pathways rather than vascular mechanisms (unlike Viagra).
Common Dosages
subcutaneous
1.75mg
As needed (45 min before) · PRN, max 8x/month
Benefits
FDA-approved for HSDD
Works within 45 minutes
Non-hormonal
As-needed dosing
Increases sexual desire
Side Effects
Nausea (40%)
Facial flushing
Injection site reactions
Headache
Vomiting
Key Research
Bremelanotide RECONNECT trials
Significant improvements in sexual desire and distress in premenopausal women
Regulatory Status
FDA-approved as Vyleesi for HSDD in premenopausal women. Prescription required.
Contraindications
- ⚠Uncontrolled hypertension
- ⚠Cardiovascular disease
- ⚠Pregnancy/breastfeeding
Not directly relevant to GLP-1 users. For specific indication of HSDD in premenopausal women.
Learn More →Find peptide providers
Search 18,000+ clinics offering peptide therapy alongside GLP-1 medications.
Search Providers →Disclaimer: This information is for educational and research purposes only. Peptides described here may not be FDA-approved for human use. Always consult a qualified healthcare provider before using any peptide product. GLP1Search does not sell peptides.